Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Bioprocessing

For many biotech innovators, high throughput screening platforms promise faster discoveries and streamlined workflows.

Bioprocessing

Why do so many promising biotech ideas stall—long before they reach the clinic or marketplace?

Innovation

Imagine medicines grown like crops, ready for harvest in days, not months.

Innovation

But what if you could grow life-saving antibodies in a greenhouse instead?

Biotech Success

Complex automation often arrives wrapped in hype, but the reality is more nuanced.

Biotech Success

Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?

Bioprocessing

Is your next blockbuster biologic doomed before your team even steps into a lab?

Bioprocessing

What if your blockbuster biologic stumbled—not because the science wasn’t there, but because no one asked if it could actually be manufactured at scale?

Bioprocessing

“Will this novel host replace CHO?” I hear this question often — and I want to be direct with you: I think it’s the wrong question.

Bioprocessing

What happens between scientific discovery and clinical trials?

Bioprocessing

Picture the difference between a “drug” and a true “product”.

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

Ever watched judges’ faces light up during your pitch?

Biotech Success

Ever stood in front of a room full of executives, your heart pounding, wondering why your brilliant science isn’t connecting?

Biotech Success

What happens when therapeutic innovation meets real patient urgency?

Biotech Success

Real urgency in healthcare means balancing safety, impact, and accessibility—not just speeding to market.

Biotech Success

What’s the single most formidable hurdle for a promising biotech breakthrough? It’s crafting a robust CMC (Chemistry, Manufacturing, and Controls) strategy.

Biotech Success

Bioprocess development and manufacturing are often perceived as sources of potential high-stakes problems, frequently cited as contributing to program failures.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Innovation

What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?

Innovation

There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.

Innovation

Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?

Innovation

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.